This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rhei, E. Articles by Boyd, J. Search for Related Content PubMed PubMed Citation Articles by Rhei, E. Articles by Boyd, J.

Molecular Genetic Characterization of BRCA1- and BRCA2-Linked Hereditary Ovarian Cancers¹

Gynecology and Breast Research Laboratory, Departments of Surgery [E. R., F. B., M. G. F., D. L. M., J. B.], Human Genetics [K. O., M. E. R., J. B.], and Pathology and Laboratory Medicine [P. E. S.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Hereditary ovarian cancers associated with germline mutations in either BRCA1 or BRCA2 were studied to determine whether somatic mutation of the P53 gene is required for BRCA-linked ovarian tumorigenesis and further, whether the spectrum of additional somatic molecular genetic alterations present in these tumors differs from that known to exist in sporadic ovarian cancers. Forty tumors, 29 linked to BRCA1 and 11 linked to BRCA2, were examined for mutational alterations in P53, K-RAS, ERBB-2, C-MYC, and AKT2. The presence of a P53 mutation in 80% of these cancers indicates that P53 mutation is common but not required for BRCA-linked ovarian tumorigenesis; notably, a significantly higher proportion of the P53 mutations in BRCA2-linked cancers were deletions or insertions compared with the more typical spectrum of missense mutations seen in BRCA1-linked cancers. Additionally, BRCA-linked ovarian carcinomas seem to develop through a unique pathway of tumorigenesis that does not involve mutation of K-RAS or amplification of ERBB-2, C-MYC, or AKT2.

¹ Supported by Grant CA71840 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Surgery, Box 201, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Received 4/29/98. Accepted 6/16/98.

This article has been cited by other articles:

				M. A. Edson, A. K. Nagaraja, and M. M. Matzuk The Mammalian Ovary from Genesis to Revelation Endocr. Rev., October 1, 2009; 30(6): 624 - 712. [Abstract] [Full Text] [PDF]

				K. A. McAllister, C. D. Houle, J. Malphurs, T. Ward, N. K. Collins, W. Gersch, L. Wharey, J. C. Seely, L. Betz, L. M. Bennett, et al. Spontaneous and Irradiation-Induced Tumor Susceptibility in Brca2 Germline Mutant Mice and Cooperative Effects with a p53 Germline Mutation Toxicol Pathol, February 1, 2006; 34(2): 187 - 198. [Abstract] [Full Text] [PDF]

				H. M. Sowter and A. Ashworth BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656. [Abstract] [Full Text] [PDF]

				T. Kirchhoff, N. D. Kauff, N. Mitra, K. Nafa, H. Huang, C. Palmer, T. Gulati, E. Wadsworth, S. Donat, M. E. Robson, et al. BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews Clin. Cancer Res., May 1, 2004; 10(9): 2918 - 2921. [Abstract] [Full Text] [PDF]

				T. Kirchhoff, J. M. Satagopan, N. D. Kauff, H. Huang, P. Kolachana, C. Palmer, H. Rapaport, K. Nafa, N. A. Ellis, and K. Offit Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 68 - 70. [Abstract] [Full Text] [PDF]

				A. A. Jazaeri, C. J. Yee, C. Sotiriou, K. R. Brantley, J. Boyd, and E. T. Liu Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers J Natl Cancer Inst, July 3, 2002; 94(13): 990 - 1000. [Abstract] [Full Text] [PDF]

				S. A. J. Vaziri, L. M. Krumroy, P. Elson, G. T. Budd, G. Darlington, J. Myles, R. R. Tubbs, and G. Casey Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis Clin. Cancer Res., July 1, 2001; 7(7): 1937 - 1945. [Abstract] [Full Text] [PDF]

				C. D. Hough, K. R. Cho, A. B. Zonderman, D. R. Schwartz, and P. J. Morin Coordinately Up-Regulated Genes in Ovarian Cancer Cancer Res., May 1, 2001; 61(10): 3869 - 3876. [Abstract] [Full Text]

				M. S. Greenblatt, P. O. Chappuis, J. P. Bond, N. Hamel, and W. D. Foulkes TP53 Mutations in Breast Cancer Associated with BRCA1 or BRCA2 Germ-line Mutations: Distinctive Spectrum and Structural Distribution Cancer Res., May 1, 2001; 61(10): 4092 - 4097. [Abstract] [Full Text]

				R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838. [Abstract] [Full Text]

				R. L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, S. Narod, and B. Y. Karlan BRCA1 Promoter Region Hypermethylation in Ovarian Carcinoma: A Population-based Study Cancer Res., October 1, 2000; 60(19): 5329 - 5333. [Abstract] [Full Text]

				H. Suzuki, F. Itoh, M. Toyota, T. Kikuchi, H. Kakiuchi, and K. Imai Inactivation of the 14-3-3 {{sigma}} Gene Is Associated with 5' CpG Island Hypermethylation in Human Cancers Cancer Res., August 1, 2000; 60(16): 4353 - 4357. [Abstract] [Full Text]

				B. A. Werness, P. Parvatiyar, S. J. Ramus, A. S. Whittemore, K. Garlinghouse-Jones, I. Oakley-Girvan, R. A. DiCioccio, J. Wiest, Y. Tsukada, B. A. J. Ponder, et al. Ovarian Carcinoma In Situ With Germline BRCA1 Mutation and Loss of Heterozygosity at BRCA1 and TP53 J Natl Cancer Inst, July 5, 2000; 92(13): 1088 - 1091. [Abstract] [Full Text] [PDF]

				J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, et al. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer JAMA, May 3, 2000; 283(17): 2260 - 2265. [Abstract] [Full Text] [PDF]

				M. M. Tanner, S. Grenman, A. Koul, O. Johannsson, P. Meltzer, T. Pejovic, A. Borg, and J. J. Isola Frequent Amplification of Chromosomal Region 20q12-q13 in Ovarian Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1833 - 1839. [Abstract] [Full Text] [PDF]

				M. Goggins, R. H. Hruban, and S. E. Kern BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia : Evidence and Implications Am. J. Pathol., May 1, 2000; 156(5): 1767 - 1771. [Abstract] [Full Text] [PDF]

				J. O. Schorge, M. G. Muto, S. J. Lee, L.-W. Huang, W. R. Welch, D. A. Bell, E. Z. Keung, R. S. Berkowitz, and S. C. Mok BRCA1-related Papillary Serous Carcinoma of the Peritoneum Has a Unique Molecular Pathogenesis Cancer Res., March 1, 2000; 60(5): 1361 - 1364. [Abstract] [Full Text]

				M. Toyota, M. Ohe-Toyota, N. Ahuja, and J.-P. J. Issa Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype PNAS, January 18, 2000; 97(2): 710 - 715. [Abstract] [Full Text] [PDF]

				M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy, A. Heerdt, P. Borgen, B. McCormick, C. Hudis, L. Norton, et al. Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations J Natl Cancer Inst, December 15, 1999; 91(24): 2112 - 2117. [Abstract] [Full Text] [PDF]

				K.-A. Phillips, K. Nichol, H. Ozcelik, J. Knight, S. J. Done, P. J. Goodwin, and I. L. Andrulis Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations J Natl Cancer Inst, March 3, 1999; 91(5): 469 - 473. [Abstract] [Full Text] [PDF]